Home

korong próza globális lung cancer overall survival verseny Tenger Szakképzett

Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer

LIBTAYO® (cemiplimab-rwlc) Overall Survival Rate in Advanced NSCLC
LIBTAYO® (cemiplimab-rwlc) Overall Survival Rate in Advanced NSCLC

Cancers | Free Full-Text | Immune Checkpoint Inhibitors after Radiation  Therapy Improve Overall Survival Rates in Patients with Stage IV Lung Cancer
Cancers | Free Full-Text | Immune Checkpoint Inhibitors after Radiation Therapy Improve Overall Survival Rates in Patients with Stage IV Lung Cancer

Modern Radiation Further Improves Survival in Non-Small Cell Lung Cancer:  An Analysis of 288,670 Patients
Modern Radiation Further Improves Survival in Non-Small Cell Lung Cancer: An Analysis of 288,670 Patients

Overall survival of patients with EGFR mutation-positive non-small-cell lung  cancer treated with erlotinib, gefitinib or afatinib under drug programmes  in Poland – real-world data
Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data

EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their  clinical outcomes: A cohort study in Taiwan
EGFR tyrosine kinase inhibitor therapy for lung cancer treatments and their clinical outcomes: A cohort study in Taiwan

Overall survival by clinical stage according to the seventh edition (A)...  | Download Scientific Diagram
Overall survival by clinical stage according to the seventh edition (A)... | Download Scientific Diagram

Real-world treatment patterns and survival outcomes for advanced non-small  cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective  analysis from the I-O Optimise initiative | BMC Pulmonary Medicine | Full
Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative | BMC Pulmonary Medicine | Full

The Effect of Advances in Lung-Cancer Treatment on Population Mortality |  NEJM
The Effect of Advances in Lung-Cancer Treatment on Population Mortality | NEJM

The Effect of Advances in Lung-Cancer Treatment on Population Mortality |  NEJM
The Effect of Advances in Lung-Cancer Treatment on Population Mortality | NEJM

Overall survival according to immunotherapy and radiation treatment for  metastatic non-small-cell lung cancer: a National Cancer Database analysis  | Radiation Oncology | Full Text
Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis | Radiation Oncology | Full Text

Prediction of survival benefits from progression-free survival benefits in  advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334  patients from 5 randomised trials | BMJ Open
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open

Median survival for metastatic ALK+ lung cancer can be more than SIX YEARS!  | Gray Connections
Median survival for metastatic ALK+ lung cancer can be more than SIX YEARS! | Gray Connections

Overall survival prediction of non-small cell lung cancer by integrating  microarray and clinical data with deep learning | Scientific Reports
Overall survival prediction of non-small cell lung cancer by integrating microarray and clinical data with deep learning | Scientific Reports

Postoperative Survival of Lung Cancer Patients: Are There Predictors beyond  TNM? | Anticancer Research
Postoperative Survival of Lung Cancer Patients: Are There Predictors beyond TNM? | Anticancer Research

A prognostic model for overall survival of patients with early-stage  non-small cell lung cancer: a multicentre, retrospective study - The Lancet  Digital Health
A prognostic model for overall survival of patients with early-stage non-small cell lung cancer: a multicentre, retrospective study - The Lancet Digital Health

Prognostic factors in resected pathological N1-stage II nonsmall cell lung  cancer | European Respiratory Society
Prognostic factors in resected pathological N1-stage II nonsmall cell lung cancer | European Respiratory Society

Many non-small cell lung cancer Medicare patients not staged according to  guidelines, leading to higher mortality rates
Many non-small cell lung cancer Medicare patients not staged according to guidelines, leading to higher mortality rates

Stage 4 Lung Cancer Life Expectancy
Stage 4 Lung Cancer Life Expectancy

5-year overall survival in patients with lung cancer eligible or ineligible  for screening according to US Preventive Services Task Force criteria: a  prospective, observational cohort study - The Lancet Oncology
5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study - The Lancet Oncology

Purpose
Purpose

Cancers | Free Full-Text | Real-World Impact of SABR on Stage I  Non-Small-Cell Lung Cancer Outcomes at a Scottish Cancer Centre
Cancers | Free Full-Text | Real-World Impact of SABR on Stage I Non-Small-Cell Lung Cancer Outcomes at a Scottish Cancer Centre

VisualAbstract: Atezolizumab monotherapy superior to chemotherapy for  treatment of non-small cell lung cancer | 2 Minute Medicine
VisualAbstract: Atezolizumab monotherapy superior to chemotherapy for treatment of non-small cell lung cancer | 2 Minute Medicine

Lung Cancer Life Expectancy | How Long Patients Live After Diagnosis
Lung Cancer Life Expectancy | How Long Patients Live After Diagnosis

Survival outcome of non-small cell lung cancer patients: Comparing results  between the database of the Comprehensive Cancer Center Zürich and the  Epidemiological Cancer Registry Zurich and Zug - Lung Cancer
Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zürich and the Epidemiological Cancer Registry Zurich and Zug - Lung Cancer

Prognostic impact of CD8 and programmed death-ligand 1 expression in  patients with resectable non-small cell lung cancer | British Journal of  Cancer
Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer | British Journal of Cancer

Real-world treatment and survival of patients with advanced non-small cell lung  Cancer: a German retrospective data analysis | BMC Cancer | Full Text
Real-world treatment and survival of patients with advanced non-small cell lung Cancer: a German retrospective data analysis | BMC Cancer | Full Text